The disparity between the rate of development of effective therapies for other breast cancers and for those predisposed by BRCA1/2 mutation can likely be attributed to inability of physically inhibiting relevant target proteins, as is possible in other breast cancers. The gene discussed is BRCA1; the disease is breast carcinoma.